Why Wegovy Changes Your Sweet Craving — and What to Do About It

What STEP 1 and appetite research found about sweet-food desire

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity or overweight and tracked body weight over 68 weeks of semaglutide 2.4mg. Average weight loss reached around 15%. But alongside that headline figure, participants in the STEP programme consistently reported reduced appetite and, specifically, lower scores for craving high-calorie foods (including sweet items) compared with placebo.

The mechanism runs deeper than stomach fullness. GLP-1 receptors sit in the hypothalamus and in dopaminergic reward pathways, the same circuits that make sugary food feel compelling in the first place. Semaglutide appears to dampen the reward signal attached to sweet taste, not just the physical hunger that drives you to seek food. That distinction matters: some people find they stop thinking about chocolate between meals before they feel notably less hungry at mealtimes.

Not everyone experiences this equally. A meaningful minority report that sweet cravings persist, or shift, wanting something sweet even when overall appetite is lower. Craving patterns are shaped by habit, stress, sleep and individual neurobiology, none of which semaglutide rewrites completely. If you want to understand why sweet cravings in particular can behave differently to other appetite changes, our page on craving sweets on Wegovy looks at the reasons behind that pattern in more detail. You can also read more about the broader picture of cravings on Wegovy, including savoury and general appetite changes.

Why sweet cravings sometimes feel stronger at certain points in treatment

The most common moment for heightened sweet cravings is during or just after a dose increase. Moving from 0.5mg to 1.0mg, or from 1.7mg to 2.4mg, temporarily shifts the GI environment: nausea, altered gastric emptying and a general sense of unsettledness can make sweet, bland or starchy foods feel more tolerable than protein-rich or fatty meals. The body is reaching for comfort and quick energy.

This tends to settle within one to two weeks as your system adjusts to the new dose level. It is not a sign that the medicine has stopped working; it reflects normal physiological adaptation. The NHS patient information for semaglutide notes that gastrointestinal effects are most pronounced early in treatment and after each increase, which is exactly when this craving shift tends to appear.

A practical approach many prescribers recommend: keep genuinely satisfying alternatives accessible during the adjustment window. Foods with adequate protein and fibre tend to give more sustained appetite suppression than high-sugar options, even when a sweet craving is pulling the other way. That said, specific dietary guidance should come from your prescriber or a registered dietitian, not a content page.

If you are curious about the sugar-craving angle specifically, our page on craving sugar on Wegovy goes further into what drives that particular pattern.

Persistent sweet cravings on Wegovy: when to mention it to your prescriber

For most people, sweet cravings reduce progressively as the maintenance dose is reached and held. For some, they remain more prominent than expected, and that is worth discussing openly with whoever is managing your treatment, rather than assuming it means the medicine is not working.

Persistent cravings can reflect a few different things: psychological habit that medication alone does not address, a dietary pattern that is not supporting appetite stability, or occasionally a sign that the current dose is not yet at the right level for that individual. The answer is rarely to push through in silence.

Behavioural support alongside medication consistently improves outcomes in the clinical literature. The NHS healthy weight guidance covers the lifestyle factors that work alongside any weight-management treatment. Small, structured changes to meal timing and composition often do more for craving stability than willpower alone.

Wegovy is a prescription-only medicine, and the right dose and support structure is a clinical judgement made by a prescriber who knows your full picture. If you are considering starting treatment, or wondering whether your current plan is optimised, it is worth getting that reviewed properly. Our free consultation connects you with a GPhC-registered prescriber who reviews your case the same day. For context on what treatment typically costs as a private patient, the Wegovy price comparison page sets out what to expect honestly. And if you have general questions about how semaglutide works as a medicine, the semaglutide overview covers the mechanism and evidence in plain language.

When you do start, your treatment arrives via tracked DPD delivery the next working day in plain, unbranded packaging, no indication on the outside of what is inside.